{
    "clinical_study": {
        "@rank": "15061", 
        "arm_group": [
            {
                "arm_group_label": "Dabigatran"
            }, 
            {
                "arm_group_label": "Warfarin"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective is to assess the safety and effectiveness of new dabigatran and warfarin\n      patients diagnosed with NVAF in the US DoD population."
        }, 
        "brief_title": "The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "detailed_description": {
            "textblock": "Study Design:\n\n      Retrospective"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients must be continuously enrolled in a health plan during the pre-index period;\n\n          -  Patients must have at least one inpatient, or one physician office visit, emergency\n             room visit with a diagnosis of AF (ICD-9-CM diagnosis code: 427.31in any position) on\n             the index date or during the pre-index period;\n\n          -  Patients must have a prescription for dabigatran or warfarin (this first prescription\n             will be the index date);\n\n          -  Patients must be treatment naive from all OAC use prior to first dabigatran or\n             warfarin prescription;\n\n          -  Aged 18-89 on the index date;\n\n        Exclusion criteria:\n\n          -  Patients with valvular procedures related to the baseline AF diagnosis will be\n             excluded;\n\n          -  Patients with transient causes of AF such as hyperthyroidism, any cardiac surgery,\n             pericarditis, mycoarditis, pulmonary embolism within 3 months prior to their first\n             diagnosis of AF;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "NVAF"
            }
        }, 
        "enrollment": {
            "#text": "17000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02043808", 
            "org_study_id": "1160.183"
        }, 
        "intervention_browse": {
            "mesh_term": "Warfarin"
        }, 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lexington", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }, 
                "name": "1160.183.01 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Stroke", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02043808"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Major lower GI bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Ischemic stroke", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Ischemic Stroke", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Hemorrhagic Stroke", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major intracranial bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major extracranial bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major GI bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major upper GI bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major urogenital bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Major other bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Transient Ischemic Attack", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Myocardial Infarction", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Venous Thromboembolism", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Deep Vein Thrombosis", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Pulmonary Embolism", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }, 
            {
                "measure": "Death", 
                "safety_issue": "No", 
                "time_frame": "up to 21 months"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}